BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21041839)

  • 1. Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.
    Tonstad S; Holme I; Tønnesen P
    Nicotine Tob Res; 2011 Jan; 13(1):1-6. PubMed ID: 21041839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H; Hurst RS
    Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
    JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
    Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
    Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
    Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
    Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
    Tonstad S; Tønnesen P; Hajek P; Williams KE; Billing CB; Reeves KR;
    JAMA; 2006 Jul; 296(1):64-71. PubMed ID: 16820548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.
    Cohen C; Bergis OE; Galli F; Lochead AW; Jegham S; Biton B; Leonardon J; Avenet P; Sgard F; Besnard F; Graham D; Coste A; Oblin A; Curet O; Voltz C; Gardes A; Caille D; Perrault G; George P; Soubrie P; Scatton B
    J Pharmacol Exp Ther; 2003 Jul; 306(1):407-20. PubMed ID: 12682217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
    Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
    Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Shiffman S
    Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.
    McCaul ME; Wand GS; Kuwabara H; Dannals RF; Wong D; Xu X
    Nicotine Tob Res; 2020 May; 22(6):892-899. PubMed ID: 31096265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers.
    Ferguson SG; Gitchell JG; Shiffman S; Sembower MA
    Clin Ther; 2009 Sep; 31(9):1957-65. PubMed ID: 19843485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
    Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
    Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varenicline for smoking cessation: a placebo-controlled, randomized study.
    Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S
    Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial.
    Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; van Schayck OC
    Addiction; 2014 Aug; 109(8):1252-9. PubMed ID: 24894625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data.
    Fagerström K; Russ C; Yu CR; Yunis C; Foulds J
    Nicotine Tob Res; 2012 Dec; 14(12):1467-73. PubMed ID: 22467778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.